🧬 Not all "Very Poor-Risk Cytogenetics’ MDS is the same with regard to allo-HCT outcome! A just published @TheEBMT study reveals a more "favorable" subgroup within a conventional ‘very poor risk’ cgn MDS allo-HCT cohort🧵👇 doi.org/10.1002/ajh.70430 📊 The 5-Year Survival Split: •Relative more Favorable Group (lacking abn5q, abn17p, or abn3q26): 46% OS •Unfavorable Group (has 1+ of these mutations): 18% OS 📉 🔮 The Takeaway: A "very poor-risk" label needs evaluation . Patients lacking abn5q, abn17p, or abn3q26 or highly complex CGN see more durable survival, while those who have them have worse outcomes and require consideration to targeted peri-transplant strategies. @TheEBMT_Trainee @CarmeloGurnari #MDSSm